Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.41 |
| ▸ | F2R | P25116 | 1/20 | 0.41 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5495665 | 0.91 | SMN1; SMN2 (0.49) | ALDH1A1SMN1; SMN2LMNACYP1A2GAA | |
| SCHEMBL8303596 | 0.91 | SMN1; SMN2 (0.49) | ALDH1A1SMN1; SMN2LMNACYP1A2GAA | |
| SCHEMBL2357857 | 0.91 | SMN1; SMN2 (0.49) | ALDH1A1SMN1; SMN2LMNACYP1A2GAA | |
| SCHEMBL1841156 | 0.89 | ALDH1A1 (0.59) | ALDH1A1SMN1; SMN2CYP1A2GAAHTT | |
| SCHEMBL6197818 | 0.89 | ALDH1A1 (0.59) | ALDH1A1SMN1; SMN2CYP1A2GAAHTT | |
| SCHEMBL2345851 | 0.82 | SMN1; SMN2 (0.51) | ALDH1A1SMN1; SMN2LMNAGAAS1PR5 | |
| SCHEMBL14159621 | 0.82 | SMN1; SMN2 (0.51) | ALDH1A1SMN1; SMN2LMNAGAAS1PR5 | |
| SCHEMBL28253726 | 0.82 | SMN1; SMN2 (0.51) | ALDH1A1SMN1; SMN2LMNAGAAS1PR5 | |
| SCHEMBL12311388 | 0.81 | PDE4B (0.43) | ALDH1A1SMN1; SMN2LMNACYP1A2GAA | |
| SCHEMBL11578382 | 0.81 | GAA (0.56) | ALDH1A1SMN1; SMN2LMNAGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8957205-B2 | Cycloalkane carboxamide derivatives and production process of same | SEIKAGAKU CORPORATION (JP) | 2015-02-17 | — | — | US | disclosed |
| US-20090156805-A1 | Cycloalkane Carboxamide Derivatives and Production Process of Same | SEIKAGAKU CORPORATION (JP) | 2009-06-18 | — | — | US | disclosed |
| EP-1972615-A1 | CYCLOALKANECARBOXAMIDE DERIVATIVE AND METHOD FOR PRODUCING SAME | SEIKAGAKU CORPORATION (JP) | 2008-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156805-A1 | Cycloalkane Carboxamide Derivatives and Production Process of Same | CTSK, CTSS, CTSB | ALDH1A1 1899/4885SMN1; SMN2 4556/4885LMNA 3170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.